Literature DB >> 22286359

[Rheumatoid arthritis and multiple myeloma as comorbidity. Is tocilizumab a therapy option?].

N Schütz1, E Märker-Hermann.   

Abstract

Multiple myeloma (MM) is a disease of the elderly with an incidence of 4/100,000 per year and can occur as a comorbidity especially in elderly patients with rheumatoid arthritis (RA). For MM and also for RA interleukin-6 (IL-6) is a pathogenetically important cytokine in both disease events. This article presents the case of a female patient who achieved sustained remission of RA and stabilization of MM with quantitative reduction of paraprotein by treatment with tocilizumab. The question whether tocilizumab represents a meaningful treatment approach for treatment of RA when MM is also present will be discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286359     DOI: 10.1007/s00393-011-0931-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  8 in total

Review 1.  Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.

Authors:  B Klein; X G Zhang; M Jourdan; J M Boiron; M Portier; Z Y Lu; J Wijdenes; J Brochier; R Bataille
Journal:  Eur Cytokine Netw       Date:  1990 Oct-Nov       Impact factor: 2.737

2.  Successful treatment of a patient with rheumatoid arthritis and IgA-κ multiple myeloma with tocilizumab.

Authors:  Yasushi Matsuyama; Takao Nagashima; Kyoko Honne; Yasuyuki Kamata; Masahiro Iwamoto; Hitoaki Okazaki; Kazuya Sato; Keiya Ozawa; Seiji Minota
Journal:  Intern Med       Date:  2011-03-15       Impact factor: 1.271

Review 3.  [Clinical application of interleukin-6 receptor antibody].

Authors:  N Nishimoto; Y Shima; M Sasai; N Danno; K Yoshizaki
Journal:  Nihon Rinsho Meneki Gakkai Kaishi       Date:  1997-04

4.  Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro.

Authors:  Toshiyuki Hirata; Chihiro Shimazaki; Toshiya Sumikuma; Eishi Ashihara; Hideo Goto; Tohru Inaba; Yasuo Koishihara; Masao Nakagawa
Journal:  Leuk Res       Date:  2003-04       Impact factor: 3.156

5.  Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor.

Authors:  Naoko Yoshio-Hoshino; Yasuo Adachi; Chieko Aoki; Alexander Pereboev; David T Curiel; Norihiro Nishimoto
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 6.  Multiple myeloma: charging toward a bright future.

Authors:  Jed A Katzel; Parameswaran Hari; David H Vesole
Journal:  CA Cancer J Clin       Date:  2007 Sep-Oct       Impact factor: 508.702

7.  Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.

Authors:  T Tamura; N Udagawa; N Takahashi; C Miyaura; S Tanaka; Y Yamada; Y Koishihara; Y Ohsugi; K Kumaki; T Taga
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

8.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.

Authors:  M Kawano; T Hirano; T Matsuda; T Taga; Y Horii; K Iwato; H Asaoku; B Tang; O Tanabe; H Tanaka
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

  8 in total
  2 in total

Review 1.  [Influence of therapy on risk of cancer in rheumatoid arthritis. Pathophysiological principles].

Authors:  M J Waldner; A Strangfeld; M Aringer
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372

Review 2.  Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.

Authors:  Michael H Tomasson; Mahmoud Ali; Vanessa De Oliveira; Qian Xiao; Yogesh Jethava; Fenghuang Zhan; Adam M Fitzsimmons; Melissa L Bates
Journal:  Int J Mol Sci       Date:  2018-11-16       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.